Meeting
2024 ASCO Annual Meeting
Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.
Authors
Miguel Angel Villalona-Calero
City of Hope National Medical Center, Duarte, CA
Miguel Angel Villalona-Calero , Glenn J. Hanna , Mark Agulnik , Monica M. Mita , Alain C. Mita , David R. Spigel , Jia Luo , Gregory Michael Cote , Jyoti Malhotra , Mohamad Adham Salkeni , Natraj Reddy Ammakkanavar , Amol Rao , Kamalesh Sankhala , Richard E. Cutler , Tressa Hood , Luis A. Carvajal , Charles Lin , Jorge F. DiMartino , Elizabeth Olek , Brian Andrew Van Tine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04718675
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3102)
DOI
10.1200/JCO.2024.42.16_suppl.3102
Abstract #
3102
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
First Author: Ben George
Poster
2024 ASCO Annual Meeting
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
First Author: Cristina Saura
Poster
2021 ASCO Annual Meeting
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
First Author: Angela Tatiana Alistar